حضير وتوصيف وتغلغل الملح الجزيئي لوسارتان - أملوديبين عبر الجلد

AlkilaniA. Z., McCrudden M. T. and Donnelly R. F. Transdermal drug delivery: innovative pharmaceutical developments based on disruption of the barrier properties of the stratum corneum. Pharmaceutics.2015; 7:438-470.

(2) Sarveiya V., Templeton J. F. and Benson H. A. Ion-pairs of ibuprofen: increased membrane diffusion. J. Pharm. Pharmacol. 2004; 56:717-724.‏

(3) Zorec B., PréatV., Miklavčič D. andPavšelj N. Active enhancement methods for intra-and transdermal drug delivery: a review. Slov. Med. J. 2013; 82.

(4) MegwaS. A., Cross S. E., Whitehouse M. W., Benson H. A. and Roberts M. S. Effect of ion pairing with alkylamines on the in-vitro dermal penetration and local tissue disposition of salicylates. J. Pharm. Pharmacol. 2000; 52:929-940‏.

(5) Valenta C., Siman U., Kratzel M. and Hadgraft J. The dermal delivery of lignocaine: influence of ion pairing. Int. J. Pharm. 2000; 197: 77-85.‏

(6) Cagigal E., Gonzalez L., Alonso R. M. and Jimenez. R. M. pKa determination of angiotensin II receptor antagonists (ARA II) by spectrofluorimetry. J. Pharm. Biomed. Anal.2001; 26:477-486.‏

(7) Vashisth I., Ahad A., Aqil M. and Agarwal S. P. Investigating the potential of essential oils as penetration enhancer for transdermal losartan delivery: effectiveness and mechanism of action. Asian J. Pharm. Sci.2014; 9:260-267.

(8) Sica D. A., Gehr T. W. and Ghosh S. Clinical pharmacokinetics of losartan. Clin.Pharmacokinet.2005; 44:797-814.

(9) Al-Dmour N. S., Abu-Dahab R. M., Evstigneev M. P., Kostjukov V. V., El-Sabawi D. and Hamdan I. I. Interaction of pseudoephedrine and azithromycin with losartan: Spectroscopic, dissolution and permeation studies. Acta A Mol. Biomol. Spectrosc. 2019; 221: 117194.

(10) Courlet P., Spaggiari D., Desfontain V., CavassiniM., SaldanhaS. A., Bucli T. and Decosterd L. A. UHPLC-MS/MS assay for simultaneous determination of amlodipine, metoprolol, pravastatin, rosuvastatin, atorvastatin with its active metabolites in human plasma, for population-scale drug-drug interactions studies in people living with HIV. J. Chromatogr.B2019;1125: 121733.‏

(11) Cho S.H., Youn Y.S., Jung Y. T., Park C. S., Lee H. K., LeeK. H. and Kang H. S. U.S., Patent no. 6,756,390. Washington, DC: U.S. Patent and trademark office, 2004.

(12) Thakuria R. and Sarma B. Drug drug and drug nutraceutical cocrystal/salt as alternative medicine for combination therapy: a crystal engineering approach. Crystals. 2018; 8:101.‏

(13) Petkar K. C.and Kuchekar B. S. In-vitro percutaneous absorption of losartan potassium in human skin and prediction of human skin permeability. DARU J. Pharm. Sci. 2007; 15:53.

(14) ThakurR., Anwer M. K., ShamsM. S., AliA., Khar R. K., Shakeel F and Taha E. I. Proniosomal transdermal therapeutic system of losartan potassium: development and pharmacokinetic evaluation. J. Drug Target. 2009; 17: 442-449.

(15) Ahad A., Al-Mohizea A. M., Al-Jenoobi F. I.andAqil M. Transdermal delivery of angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme inhibitors (ACEIs) and others for management of hypertension. Drug Deliv.2016; 23:579-590.

(16) Bartosova L.and Bajgar J. Transdermal drug delivery in vitro using diffusion cells. Curr. Med. Chem. 2012; 19:4671-4677.

(17) GroenD., Gooris G. S., Ponec M.and Bouwstra J. A. Two new methods for preparing a unique stratum corneum substitute. Biochim. Biophys. Acta. 2008; 1778:2421-2429.

(18) Raman N. V. V. S. S., Reddy K. R., Prasad A. V. S. S. and Ramakrishna K. Development and validation of RP-HPLC method for the determination of genotoxic alkyl benzenesulfonates in amlodipine besylate. J. Pharm. Biomed. Anal. 2008; 48:227-230.‏

(19) Bouabdallah S., Trabelsi H., Driss M. R. and Touil S. Determination and degradation study of enalapril maleate by high performance liquid chromatography. Pharm. Chem. J.2017; 51:735-741.

(20) Azharuddin M., Kamath K., Panneerselvam T., Pillai S. S. and Shabaraya A. R. Formulation and evaluation of controlled release matrix tablets of antihypertensive drug using natural and synthetic hydrophilic polymers. Res. Biotech. 2011; 2:26-32.

(21) Pant T., Mishra K. and Subedi R. K. In vitro studies of amlodipine besylate tablet and comparison with foreign brand leader in Nepal. Int. J. Pharm. Sci. Res. 2013; 4:3958.

(22) Rai. Aand Sharma S. Preparation and evaluation of oral dispersible

formulations of amlodipine besylate. Asian J. Pharm. Res. Develop.2019; 7:42.

(23) Tran H.T.T., Park J.B., Hong K.H., Choi H.G., Han H.K., Lee J., Lee B. J. Preparation and characterization of pH-independent sustained release tablet containing solid dispersion granules of a poorly water-soluble drug. Int. J. Pharm. 2011;415:83-88.

(24) Silva A.C.M., Gálico D.A., Guerra R.B., Perpétuo G.L., Legendre A.O., Rinaldo D. and Bannach G. Thermal stability and thermal decomposition of the antihypertensive drug Amlodipine besylate. J. Therm. Anal. Calorim.2015; 120:889-892.‏

(25) Yuan X. and Capomacchia A.C. Influence of physicochemical properties on the in vitro skin permeation of the enantiomers, racemate, and eutectics of ibuprofen for enhanced transdermal drug delivery. J. Pharm. Sci.2013;102:1957-1969.

(26) MacFarlane D.R., Kar M. and Pringle J.M. Fundamentals of ionic liquids:

from chemistry to applications, First Edition. Wiley-VCH Verlag GmbH and Co. KGaA. 2017.

(27) Sidat Z., Marimuthu, T., Kumar P., du ToitL. C., Kondiah P.P., ChoonaraY. E. and PillaV. Ionic liquids as potential and synergistic permeation enhancers for transdermal drug delivery. Pharmaceutics.2019; 11:96.

(28) BojjaR.and Satyanandam R. Design and development of pulsincap for chronopharmaceutical drug delivery of losartan potassium. Asian J. Pharm. Res. Develop. 2014;78-86.

(29) Mubtasim N., Kabir E. R., Podder A. K. and BhadraS. A pragmatic approach to the analysis of a combination formulation. Saudi Pharm. J. 2016; 124:689.

(30) Zervou M., Cournia Z., Potamitis C., Patargias G., Durdagi S., Grdadolnik S. G. and Mavromoustakos, T. Insights into the molecular basis of action of the AT1 antagonist losartan using a combined NMR spectroscopy and computational approach. Biochim. Biophys. Acta 2014; 1838:1031-1046.

(31) Szabo L., ChişV., Pîrnău A., Leopold N., CozarO.and Orosz S. Spectroscopic and theoretical study of amlodipine besylate. J. Mol. Struct. 2009; 924:385-392.

(32) JingY. Q., LiZ. R., Wu, D., Li Y., Wang B.Q. and Sun C.C. Characteristics of antiaromaticring π multi-hydrogen bonds in (H2O) n− C4H4 (n= 1, 2) complexes. J. Phys. Chem. A. 2006;110:7470-7476.

(33) Ringer A.L., Figgs M.S., Sinnokrot M.O. and Sherrill C.D. Aliphatic C− H/π interactions: methane− benzene, methane− phenol, and methane− indole complexes. J. Phys. Chem. A. 2006; 110:10822-10828.‏

(34) Nicolazzo J.A., Morgan T.M., Reed B.L.and Finnin B.C. Synergistic enhancement of testosterone transdermal delivery. J. Controlled Rel.2005; 103:577-585.‏

(35) WittingM., BorehamA., Brodwolf R., Vavrova K., AlexievU., Friess W.and HedtrichS. Interactions of hyaluronic acid with the skin and implications for the dermal delivery of biomacromolecules. J. Mol. Pharm. 2015; 12:1391-1401.

(36) Barbero A. M. and Frasch H. F. Pig and guinea pig skin as surrogates for human in vitro penetration studies: a quantitative review. Toxicol. In. Vitro. 2009;23:1-13.

(37) Anissimov Y.G.and Roberts M.S. Diffusion modeling of percutaneous absorption kinetics. 1. Effects of flow rate, receptor sampling rate, and viable epidermal resistance for a constant donor concentration. J. Pharm. Sci. 1999; 88:1201-1209.‏

(38) Tarawneh RT., Mansour RS, El-Sabawi D., Hamdan II. Preparation and Physicochemical Characterization of Atorvastatin Choline Salt and its Potential for Transdermal Permeation. J. J. Phar. Sci. 2020; 13: 1-19.